Zymeworks to Present at Bloom Burton Healthcare Conference

Zymeworks\xe2\x80\x99 suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, April 13, 2021
Information
Tags: 
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Life sciences, Pharmaceutical industry, Health sciences, Biotechnology, Biopharmaceutical, Pharmacy, Medication
Geotags: 
United States, Canada, BRITISH COLUMBIA
⚠generated by AI ↴
Summary
Key Points: 
  • Zymeworks\xe2\x80\x99 suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates.
  • Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas.
  • In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.
  • For additional information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on Twitter.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210413005077/en/\n'


Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the Company will present at the upcoming 2021 Bloom Burton Healthcare Investor Conference taking place April 20-21, 2021.

The Company’s presentation will be on Tuesday, April 20, 2021 at 11:30 a.m. ET.

Interested parties can access a live webcast of the presentation via a link from Zymeworks’ website at http://ir.zymeworks.com/events-and-presentations, which will also host a recorded replay available afterwards.

About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab (ZW25), is a novel Azymetric™ bispecific antibody which has been granted Breakthrough Therapy designation by the FDA and is currently enrolling in a pivotal clinical trial for refractory HER2-amplified biliary tract cancer (HERIZON-BTC-01) as well as several Phase 2 clinical trials for HER2-expressing gastroesophageal and breast cancers. Zymeworks’ second clinical candidate, ZW49, is a novel bispecific HER2-targeting antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies. For additional information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on Twitter.

Copyright: 
Copyright Business Wire 2021